ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Durham, NC, USA:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: LoDAC (Low Dose Cytarabine)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)

Phase 3

Astellas
Astellas

Durham, North Carolina, United States and 125 other locations

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Chapel Hill, North Carolina, United States and 164 other locations

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS.For...

Active, not recruiting
Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome (MDS)
Biological: MBG453
Drug: HDM201

Phase 1

Novartis
Novartis

Durham, North Carolina, United States and 8 other locations

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...

Active, not recruiting
AML
Acute Myelogenous Leukemia
Drug: Conventional Care
Drug: Iomab-B

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Chapel Hill, North Carolina, United States and 23 other locations

A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia...

Enrolling
Acute Myeloid Leukemia (AML)
Drug: ZN-c3
Drug: ZN-d5 ZN-c3

Phase 1, Phase 2

K-Group Alpha

Chapel Hill, North Carolina, United States of America and 12 other locations

Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute...

Active, not recruiting
AML, Adult
Acute Myeloid Leukemia
Drug: venetoclax
Drug: azacitidine

Phase 1, Phase 2

ALX Oncology

Durham, North Carolina, United States and 4 other locations

to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy.Participants will...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Pevonedistat

Phase 2

Takeda
Takeda

Chapel Hill, North Carolina, United States and 56 other locations

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute...

Enrolling
Relapsed or Refractory Acute Myeloid Leukemia
Drug: Tuspetinib
Drug: Venetoclax Oral Tablet

Phase 1, Phase 2

Aptose Biosciences

Durham, North Carolina, United States and 33 other locations

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: MBG453

Phase 2

Novartis
Novartis

Durham, North Carolina, United States and 27 other locations

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Durham, North Carolina, United States and 222 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems